Anti-Hypertensive Forecast Says Market Will Be Volatile

The anti-hypertensive market will be volatile in the next five years due to patent expiries of blockbuster drugs, says the newly released report from Transparency Market Research.

Hypertension is a lifelong disease in which the arterial blood pressure is persistently elevated at or above 140/90mm Hg level. The chronic condition is also known as arterial hypertension or high blood pressure, in general. Primary hypertension has no known underlying medical cause and is more prevalent than secondary hypertension, which results from other disorders such as kidney, heart, or endocrine conditions.

According to the World Health Organization, complications of hypertension account for 9.4 million deaths worldwide every year.  Hypertension is responsible for at least 45% of deaths due to heart disease and 51% of deaths due to stroke. Hypertension remains one of the key factors for cardiovascular morbidity and mortality.

The anti-hypertensive drugs market is classified based on their therapeutic class: diuretics, angiotensin receptor blockers (ARBs), angiotensin converting enzyme (ACE) inhibitors, calcium channel blockers, alpha blockers, beta blockers, vasodilators and renin inhibitors. These may be used as single drug administration or in fixed dose combinations. Drug preference for the treatment of hypertension depends on the medical history of the patient and their current condition.

The demand for anti-hypertensive drugs is considered sustainable since the condition is a lifelong disease. Patients are often required to take medications every day for the rest of their lives. According to the study, anti-hypertensive drugs were the second largest therapy area in 2011, with global sales value of over $40 billion (Evaluate Pharma World Preview 2018 report).

The report says the market will be rocked in 2013-2019 by patent expiries of blockbuster drugs including Diovan, Revatio, Exforge, and Avapro, among others. The market will also be impacted by generic erosion and the launch of novel molecules. In addition, factors such as lifestyle modifications and aging populations are expected to lead an increase in the global hypertension incidence rate.

Key players in the global anti-hypertensive drugs market include Novartis AG, Astra Zeneca Plc, Daiichi Sankyo Company Limited, Takeda Pharmaceutical Company Limited, Novartis AG, Pfizer, Inc., Johnson & Johnson Ltd., Sanofi S.A., Lupin Limited, Ranbaxy Laboratories Limited, and Merck & Co., Inc.

Source:

http://www.transparencymarketresearch.com/anti-hypertensive-drugs.html